Psomagen, Inc.
KOSDAQ-listed genomics company offering NGS, single-cell, and proteomics analysis plus the Kean Gene DTC genetic test.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2004 and listed on KOSDAQ in 2020, Psomagen is a genomics analysis service company. It offers next-generation sequencing (NGS) and capillary electrophoresis sequencing (CES)-based genomic analysis, the direct-to-consumer genetic test Kean Gene, single-cell analysis, proteomics analysis, and the C9orf72 Assay for neurological disease genes. It obtained CSP certification from 10x Genomics, NanoString, and Sweden's Olink Proteomics, adopting the Chromium X, CosMx, and Q100 platforms respectively; it commercialized clinical whole-transcriptome analysis in collaboration with Mindera Health of the US; and it plans to complete development of 15 WES/WGS-based cancer panels, including a Hereditary Cancer Panel, within 2026.
Products & technology
- NGS analysis serviceWhole-genome/exome, RNA/transcriptome, single-cell, and metagenomics analysis
- CES analysis serviceCapillary electrophoresis sequence verification
- Kean GeneDirect-to-consumer genetic test
- Single-cell analysis serviceSingle-cell gene expression analysis
- Proteomics analysis serviceProtein-based biomarker analysis (Targeted panel, Explore service)
- C9orf72 AssayAnalysis of the C9orf72 gene linked to frontotemporal dementia and ALS
R&D and key agreements
Source: DART corporate disclosure유전성 망막질환 패널 · 유전성 망막질환 · 개발완료, 서비스 준비중 · Plan shifted from panel-based testing to WGS/WES-based diagnostics
Cancer Panel(Hereditary Cancer Panel 등 15개 패널) · 유전성 암 등 · 개발중, 2026년 내 개발완료 예상 · WES/WGS-based
Targeted Panel 분석기술 · 연구용 유전자 분석 · 연구서비스 제공중
임상 전장전사체분석 · 연구 및 진단 · 상용화 완료 · Developed with Mindera Health (US) under a distributive assay model
인종별 장내미생물군 데이터베이스 · 마이크로바이옴 · 구축중 · Uses whole meta-genome sequencing
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition